Blog
RSS FeedPosted by Michael Wonder on 24 May 2022
NICE doesn’t recommend ibrutinib for those with Waldenstrom’s macroglobulinaemia
23 May 2022 - Ibrutinib, a drug used to treat Waldenström’s macroglobulinaemia, is not being recommended by NICE in England ...
Posted by Michael Wonder on 24 May 2022
Thousands of people in England could benefit after NICE recommends treatment option for two forms of sight loss
24 May 2022 - NICE recommends faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. ...
Posted by Michael Wonder on 24 May 2022
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
24 May 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 May 2022
NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills
20 May 2022 - Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be ...
Posted by Michael Wonder on 19 May 2022
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread
17 May 2022 - A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the ...
Posted by Michael Wonder on 16 May 2022
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS
16 May 2022 - Durvalumab recommended as an option for treating non-small-cell lung cancer. ...
Posted by Michael Wonder on 11 May 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
11 May 2022 - NICE has published evidence based recommendations on the use of avelumab for adults with locally advanced ...
Posted by Michael Wonder on 05 May 2022
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
5 May 2022 - NICE has published evidence based recommendations on the use of selumetinib (Koselugo) for the treatment of children ...
Posted by Michael Wonder on 27 Apr 2022
Tucatinib for adults with HER2 positive advanced breast cancer
27 April 2022 - NICE has published evidence-based recommendations on the use of tucatinib for the treatment of adults with ...
Posted by Michael Wonder on 27 Apr 2022
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia
27 April 2022 - NICE has published evidence-based recommendations on the use of venetoclax in combination with low dose cytosine ...
Posted by Michael Wonder on 20 Apr 2022
NICE terminates appraisal of nivolumab
20 April 2022 - This is the first appraisal of nivolumab to be terminated by NICE. ...
Posted by Michael Wonder on 14 Apr 2022
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation
14 April 2022 - An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced ...
Posted by Michael Wonder on 13 Apr 2022
NICE backs Biogen’s Vumerity for multiple sclerosis
13 April 2022 - Patients with relapsing-remitting multiple sclerosis in England, Wales and Northern Ireland can now access treatment with ...
Posted by Michael Wonder on 09 Apr 2022
Upadacitinib, abrocitinib and tralokinumab for atopic dermatitis
8 April 2022 - A rare multiple technology assessment from NICE. ...
Posted by Michael Wonder on 08 Apr 2022
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within ...